U.S. markets close in 30 minutes
  • S&P 500

    3,849.95
    -3.12 (-0.08%)
     
  • Dow 30

    31,072.00
    -104.01 (-0.33%)
     
  • Nasdaq

    13,554.08
    +23.16 (+0.17%)
     
  • Russell 2000

    2,153.40
    +11.98 (+0.56%)
     
  • Crude Oil

    52.13
    -1.00 (-1.88%)
     
  • Gold

    1,855.50
    -10.40 (-0.56%)
     
  • Silver

    25.55
    -0.31 (-1.20%)
     
  • EUR/USD

    1.2173
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    1.0910
    -0.0180 (-1.62%)
     
  • GBP/USD

    1.3679
    -0.0051 (-0.37%)
     
  • USD/JPY

    103.8200
    +0.3150 (+0.30%)
     
  • BTC-USD

    33,792.09
    +3,308.34 (+10.85%)
     
  • CMC Crypto 200

    668.34
    +58.35 (+9.57%)
     
  • FTSE 100

    6,695.07
    -20.35 (-0.30%)
     
  • Nikkei 225

    28,631.45
    -125.41 (-0.44%)
     

China's Sinovac COVID-19 vaccine proves effective in Brazil trials - WSJ

·1 min read

Dec 21 (Reuters) - Chinese vaccine maker Sinovac Biotech's COVID-19 vaccine has shown to be effective in late-stage trials in Brazil, the Wall Street Journal reported on Monday, citing people involved in the vaccine's development.

Sinovac and AstraZeneca Plc's vaccine candidates may be ready for use in Brazil by mid-February, the country's health minister said last week.

Brazil is the first country in the world to complete late-stage trials of Sinovac's vaccine, CoronaVac, which is also being tested in Indonesia and Turkey, the Journal reported https://www.wsj.com/articles/sinovacs-covid-19-vaccine-shown-to-be-effective-in-brazil-trials-11608581330?mod=latest_headlines.

Sao Paulo state's Butantan Institute is organizing the late-stage trials of CoronaVac in Brazil.

The results from the Brazil trials put CoronaVac above the 50% threshold that international scientists deem necessary to protect people, the Journal report said.

Butantan is poised to announce on Wednesday CoronaVac's efficacy rate, according to the Wall Street Journal.

Butantan Institute and Sinovac did not immediately respond to Reuters' requests for comment.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Maju Samuel)